ArticleJournal of microbiology (Seoul, Korea)2018
Colistin resistance in Enterobacter spp. isolates in Korea.
Article in Journal of microbiology (Seoul, Korea), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- First report and genomic characterization of an mcr-10.1-carrying Enterobacter kobei strain isolated from a domestic kitchen sink in China.BMC microbiology · 2026Article
- Detection and Characterization of Colistin Heteroresistance in an Enterobacter cloacae ST48 Strain Isolated From Raw Milk in Algeria.Veterinary medicine and science · 2025Article
- Colistin heteroresistance, mechanisms, diagnostic methods, and therapeutic options: A review.Germs · 2025Review
- Emergence of concurrently transmissibleMicrobiology spectrum · 2025Article
- Polymyxin resistance in Enterobacter cloacae complex in Brazil: phenotypic and molecular characterization.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Genomic Study of High-Risk Clones ofAntibiotics (Basel, Switzerland) · 2024Article
- High prevalence of colistin heteroresistance in specific species and lineages of Enterobacter cloacae complex derived from human clinical specimens.Annals of clinical microbiology and antimicrobials · 2023Article
- Species identification, antibiotic resistance, and virulence inFrontiers in microbiology · 2023Article
- Global colistin use: a review of the emergence of resistant Enterobacterales and the impact on their genetic basis.FEMS microbiology reviews · 2022Review
- Detection of an IMI-2 carbapenemase-producingFrontiers in microbiology · 2022Article
- Antibacterial Activity of LCB10-0200 againstAntibiotics (Basel, Switzerland) · 2021Article
- Two Distinct Genotypes of KPC-2-ProducingAntibiotics (Basel, Switzerland) · 2021Article
- Antibiotic resistance and persistence-Implications for human health and treatment perspectives.EMBO reports · 2020Review
- PmrAB and PhoPQ Variants in Colistin-Resistant Enterobacter spp. Isolates in Korea.Current microbiology · 2019Article
- Article
- Analysis of colistin resistance in carbapenem-resistantTherapeutic advances in infectious diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigated the colistin resistance rate among 356 Enterobacter spp. clinical isolates from eight hospitals in Korea. Antibiotic susceptibility testing was performed by broth microdilution. While 51 of 213 (23.9%) Enterobacter cloacae isolates were colistin-resistant, only six of 143 (4.2%) E. aerogenes isolates showed resistance. We also identified the skip well phenotype in eight E. cloacae and three E. aerogenes isolates. Multilocus sequence typing for E. cloacae and randomly amplified polymorphic DNA analysis and enterobacterial repetitive intergenic consensus PCR for E. aerogenes revealed that clonal spreading of colistin-resistant and skip well Enterobacter spp. isolates had not occurred. In vitro time-kill assays were performed with three colistin-resistant, three skip well, and two colistin-susceptible isolates of E. cloacae and E. aerogenes. Inconsistent results were observed among isolates with skip well phenotypes; while some were eradicated by 2 mg/L colistin, others were not. This suggests that skip well isolates have differentiated into different categories. As the high rates of colistin resistance in E. cloacae detected are of clinical concern, continuous monitoring is warranted. In addition, the clinical implications and mechanisms of the skip well phenotype should be investigated to ensure the appropriate use of colistin against Enterobacter infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.